

Important information regarding Humira® and Stelara® Biosimilar Strategy

There are currently several biosimilars of Humira® and Stelara® available on the market. A biosimilar is a highly similar version of an already approved biologic drug known as a reference product. Biosimilars are rigorously tested for safety and effectiveness to ensure they provide the same therapeutic benefits as the reference product.

As part of our commitment to stewardship and delivery of quality care, Security Health Plan will **remove** Humira® and Stelara® from the formulary **effective Tuesday, July 1, 2025**, for all Commercial and Marketplace lines of business. Patients will be required to switch to a preferred biosimilar.

Brand or Reference Product	Preferred Biosimilar	Copay Assistance Card	Interchangeable	Concentrations
Humira® (adalimumab)	adalimumab-adaz	Yes	Yes*	*Pre-filled Syringe 10 mg/0.1 mL 10 mg/0.2 mL 20 mg/0.2 mL 20 mg/0.4 mL 40 mg/0.8 mL 80 mg/0.8 mL
	Simlandi® (adalimumab-ryvk)	Yes	Yes*	*Autoinjector and Pre-filled Syringe 40 mg/0.4 mL
Stelara® (ustekinumab)	Yesintek® (ustekinumab-kfce)	Yes	No	Single-dose Vial 45 mg/0.5 mL Pre-filled Syringe 45 mg/0.5 mL, 90 mg/mL IV Infusion Only 130 mg/26 mL
	Selarsdi® (ustekinumab-aekn)	Yes	No	Pre-filled Syringe 45 mg/0.5 mL, 90 mg/mL IV Infusion Only 130 mg/26 mL

*Only certain strengths and dosage forms are interchangeable; the best practice is to send a new prescription to your patient's pharmacy to ensure the correct switch is made.

All patients currently receiving Humira[®] and Stelara[®] will be required to switch unless they have an approved formulary exception request for the brand or reference product.

If you have patients currently on Humira[®] or Stelara[®], please send in new prescriptions for one of the preferred biosimilars to the patient's pharmacy. We encourage patients to convert before the deadline to avoid delays in therapy.